Track topics on Twitter Track topics that are important to you
Patient dosing is underway in the TIME-2b clinical trial of AKB-9778 to treat moderate to severe nonproliferative diabetic retinopathy, according to a press release from Aerpio Pharmaceuticals.The double-masked, placebo-controlled, multicenter phase 2b trial will include 150 participants with diabetic retinopathy receiving AKB-9778 15 mg subcutaneously once daily, the same drug twice daily or a placebo for 12 months.
Original Article: Aerpio begins dosing in trial of diabetic retinopathy treatmentNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...